Skip to content

Microbot Medical MBOT Common Stock Shares Authorized

Other financials

Income statement

See full
Revenue$105.0K
Gross profit$2.0K
Operating income-$4.3M-43.0%
Net income-$3.7M-41.1%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$3.7M+13.7%
Total debt$898.0K+551%
Total equity$74.1M+156%
Total assets$78.1M+153%

Cash flow

See full
Operating cash flow-$5.1M-75.8%
CapEx$108.0K+731%
Free cash flow-$5.2M-78.8%

Valuation

See full
Market cap$128.28M+36.1%
Enterprise value$125.53M+39.0%
P/S674.3×

Profitability

See full
Operating margin25,292.9%
Net margin-3,669.9%
FCF margin-852.8%

Returns & leverage

See full
Return on equity-27.6%-10.2pp
Debt / equity0.0×
Current ratio22.6×+6.4×

Where this comes from

Reported directly by Microbot Medical in its filing.

Tagged under the XBRL concept us-gaap:CapitalUnitsAuthorized.

The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Microbot Medical's common stock shares authorized.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Microbot Medical's common stock shares authorized?
Microbot Medical (MBOT) reported common stock shares authorized of 61M in Q2 2025.
What is the long-term trend for Microbot Medical's common stock shares authorized?
Over 4 years (2020 to 2024), Microbot Medical's common stock shares authorized has grown at a 44.3% compound annual growth rate (CAGR), from 575.7K to 2.5M.
What does common stock shares authorized mean?
The maximum number of common shares that the company is legally permitted to issue as defined by its articles of incorporation. This figure sets the upper limit for potential equity financing and dilution. Investors monitor this to understand the company's capacity to raise capital through future share offerings.